Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD
Q4 2024 Management View CEO George Lasezkay highlighted the company's progress in advancing its suprachoroidal delivery platform, noting over 15,000 suprachoroidal injections performed to date. He ...
P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M
Q4 2024 Management View CEO Aric Coffman highlighted the company's focus on achieving near-term profitability, supported by programmatic initiatives targeting over $130 million in adjusted EBITDA ...